Support great content
Help us bring you the AM insights that matter
BiomaterialsBioprintingMaterials

Allevi and Lonza collaborate on new bioink development

Allevi and Lonza, a major Swiss CDMO, have formed a collaboration to bring the elements needed for 3D bioprinting together. Combining Lonza’s primary cells and media with Allevi’s 3D bioprinters and bioink production capabilities will empower researchers with the tools needed for plug-and-play bioprinting.

One of the biggest setbacks on bioprinting advancements is the availability of viable and functional cellular materials. Much like in AM, the technologies may be slow but they are there and ready for creating commercial applications, they are just not been exploited to the fullest.

Allevi is one of the companies developing affordable bioprinting hardware and is dedicated to providing high-quality materials for every step of the 3D bioprinting workflow, making it easy to design, engineer, and manufacture 3D tissues. Their 3D bioprinters and bioinks are used by leading researchers globally in research drug discovery and tissue engineering.

Allevi and Lonza,

Lonza Biosciences is a global leader in cell biology solutions, offering a broad range of high-quality human-derived primary cells, stem cells and supporting culture media that are ideally suited for 3D cell culture and 3D bioprinting.

3D bioprinting has been gathering a lot of media attention recently, as new potential applications seem closer to exploring commercial viability. Several scientists now agree that bioprinting is a promising technology for engineering of complex 3D tissues needed in many areas of in vitro drug discovery research. High-quality cells are the essential building block for creating 3D bioprinting constructs and can be printed in physiological relevant patterns using this technology.

Lonza collaborates with selected providers of 3D printing technology to bring the best cell and media tools to 3D bioprinting applications. Allevi customers will now have access to Lonza primary cells and media for use in Allevi’s protocols for 3D bioprinting.

 

Tags

Davide Sher

Since 2002, Davide has built up extensive experience as a technology journalist, market analyst and consultant for the additive manufacturing industry. Born in Milan, Italy, he spent 12 years in the United States, where he completed his studies at SUNY USB. As a journalist covering the tech and videogame industry for over 10 years, he began covering the AM industry in 2013, first as an international journalist and subsequently as a market analyst for leading US-firm SmarTech Analysis, focusing on the additive manufacturing industry and relative vertical markets. In 2016 he Co-founded London-based 3dpbm. Today the company publishes the leading news and insights websites 3D Printing Media Network and Replicatore, as well as 3D Printing Business Directory, the largest global directory of companies in the additive manufacturing industry.

Related Articles

Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Close
Close

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!